Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhibition of Anaphylaxis by Ibrutinib

NCT03149315 is registered in ClinicalTrials.gov with Ann & Robert H Lurie Children's Hospital of Chicago as lead sponsor.

NCT NCT03149315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03149315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhibition of Anaphylaxis by Ibrutinib
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Phase
Phase 2
Overall status
Completed
Start date
April 10, 2017
Completion date
November 14, 2018
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaphylaxis food, food allergy